eople who have had a stroke or transient ischemic attack (TIA) are at increased risk of subsequent stroke. Of the ≈795 000 strokes that occur each year in the United States, 23% are recurrent events, placing an immense burden on the healthcare system. 1 Currently established risk factors and risk prediction models do not fully identify people who will or will not have a stroke after a stroke or TIA.
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not associated with the risk of a second stroke in another. 9 Lipoprotein-associated phospholipase A 2 (LpPLA 2 ), another inflammatory biomarker, had a modest association with both first 10 and recurrent 9 strokes. The placebo-controlled SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) showed that intense lipid lowering with atorvastatin 80 mg/d reduced the risk of fatal or nonfatal stroke by 16% in 4731 patients with a recent stroke or TIA and no known coronary heart disease (CHD). 11 The primary aim of the present case-cohort analysis of the SPARCL trial was to evaluate whether 13 plasma biomarkers that are key components of the inflammatory, thrombotic, and oxidative stress cascades might better identify those at relatively higher risk of recurrent cerebrovascular events. Secondary aims were to determine whether any biomarkers found to be associated with outcome strokes, individually or in combination, improved on an existing recurrent stroke risk prediction model (the Stroke Prognostic Instrument-II [SPI-II] 3 ) and if any of the biomarkers modified the therapeutic effect of atorvastatin.
Materials and Methods

Study Design and Patient Population
The study sponsor is committed to providing researchers access to patient-level trial data. Please see http://www.pfizer.com/science/ clinical-trials/trial-data-and-results for further details. The design of the SPARCL trial has been described previously. 11 The primary hypothesis was that treatment with 80 mg/d of atorvastatin would reduce the combined risk of fatal and nonfatal stroke among patients with a recent stroke or TIA. Men and women >18 years of age were eligible who had had an ischemic or hemorrhagic stroke or a TIA 1 to 6 months before randomization. Stroke was defined by focal clinical signs of central nervous system dysfunction of vascular origin that lasted for at least 24 hours; TIA was defined by the loss of cerebral or ocular function for <24 hours from a presumed vascular cause, regardless of neuroimaging evidence of ischemic injury. Patients had to be ambulatory (modified Rankin Scale score ≤3) and have an LDL (low-density lipoprotein) cholesterol level 100 to 190 mg/dL; 15 of 205 centers excluded otherwise suitable patients with LDL cholesterol >160 mg/dL, as mandated by their institutional review boards. Patients were excluded if they had a history of CHD, significant peripheral artery disease, atrial fibrillation or prosthetic heart valves (potential sources of cardioembolic strokes), uncontrolled hypertension, stroke caused by a revascularization procedure (as qualifying entry event), subarachnoid hemorrhage, active liver disease, or severe renal dysfunction. Patients with hemorrhagic stroke (2% of the study population) could be included if they were deemed by the investigator to be at risk for ischemic stroke or CHD. Participants were enrolled between September 1998 and March 2001. Assessment of carotid stenosis in SPARCL was done at investigator discretion and was not centrally adjudicated. It was described in the case report forms as present, absent, or unknown. 12 The local research ethics committee or institutional review board approved the study protocol, and all patients gave written informed consent.
The primary outcome of the SPARCL trial was the time from randomization to a first nonfatal or fatal stroke. An independent end-point committee adjudicated all end points, including all potential strokes, without knowledge of the patients' treatment status or lipid levels.
We analyzed data from 2176 SPARCL trial participants including 562 of 576 cases with strokes who had blood samples available and 1614 participants without strokes randomly selected through a case-cohort design. Within the case-cohort design, the subcohort also included 210 patients with strokes, with a total subcohort thus consisting of 1824 participants. Analyses of this case-cohort study took the selection of these 210 patients into consideration and made the estimated event rates and associated comparisons applicable to the entire SPARCL cohort.
13
Biomarkers
The 13 biomarkers (Table 1) include both high-sensitivity CRP (hsCRP) and LpPLA 2 in addition to 11 other biomarkers, in part selected based on their reported relationship with the risk of nonstroke cardiovascular events. These candidate biomarkers reflect key components of inflammation, thrombosis, and oxidative stress (Table 1) .
Biomarker Analyses
Blood was collected into tubes containing EDTA, centrifuged on site, and the plasma was stored at a core laboratory at −70°C until analyzed (Millipore BioPharma Services Laboratory, St Charles, MO). We conducted a preliminary study to determine the effect of freezethaw cycles on biomarker stability. The effects of up to 4 freezethaw cycles were at most minor. Nevertheless, plasma samples for our analysis were typically aliquoted at the first thaw and analyzed promptly. Additional details of each biomarker assay are provided in Table 1 . The coefficients of variation for each of the 13 biomarker assays are shown in Table I in the online-only Data Supplement.
Statistical Analyses
Baseline characteristics of participants were compared between groups using a χ 2 test for categorical variables and a Wilcoxon ranksum test for continuous variables. The association between baseline biomarker level and outcome stroke was assessed using Cox proportional hazard models adapted to case-cohort design, 13 with stroke as the dependent variable and each biomarker as an independent variable. The adaptation uses the event rate in the subcohort, which appropriately represents the event rate in the total SPARCL population and estimates a hazard ratio (HR) that is applicable to the entire SPARCL patient population. The proportional hazard models were fit with the procedure 'cch' within the R package 'survival,' a method developed for case-cohort data analysis.
14 All other analyses were performed in SAS. Ischemic or hemorrhagic stroke outcomes were analyzed similarly. Both unadjusted and adjusted (for age, sex, race [white/nonwhite], treatment group, smoking status, diabetes mellitus, systolic blood pressure, hypertension treatment, high-density lipoprotein cholesterol, apolipoprotein A1, entry event [stroke or TIA], time since entry event, and geographic region) analyses were performed. The fully adjusted model included variables that were either prespecified based on the published literature or were associated with outcome strokes (P<0.10) in univariate analyses. The treatment-bybaseline biomarker interactions were assessed separately in the same model by adding the interaction term to test for heterogeneity in the effect of biomarkers among atorvastatin-and placebo-treated participants. The HR and 95% confidence intervals (CI) that correspond to 1-SD increase were obtained.
Logistic regression analyses were used to evaluate the associations of biomarkers with outcome strokes, after adjusting for study treatment and the SPI-II. The SPI-II, which has been extensively validated, uses 7 clinical factors (congestive heart failure, diabetes mellitus, prior stroke, age >70 years, stroke as index event, severe hypertension, and coronary artery disease) to estimate the risk of stroke (or death) in patients with prior TIA or nondisabling ischemic stroke. 3 Biomarkers that were significant predictors in the logistic regression analyses were further evaluated by calculating the associated incremental area under the receiver operating characteristic (ROC) curves, the continuous net reclassification improvement (NRI), and the integrated discrimination improvement (IDI). 15, 16 An SAS macro was used to calculate area under the ROC curve, NRI, and IDI. 17 Statistical significance was set at P<0.05; as this was an exploratory analysis, no adjustment was made for multiple comparisons. The study had a 90% power to detect a difference in each biomarker between the cases and controls (2 sample t-tests; Tables II and III in the online-only Data Supplement).
The SPARCL steering committee and Dr Ganz developed and executed the study protocol with the sponsor and take responsibility for the data and their analyses.
Results
As for the entire SPARCL cohort, 11 the median duration of follow-up in this substudy was 5.0 years. Baseline clinical characteristics and lipid/lipoprotein levels of the 2176 substudy participants were similar to the overall SPARCL cohort ( Table 2) . As in the overall SPARCL cohort, 11 biomarker substudy participants who had an outcome stroke were older, more often men, nonwhite, hypertensive, diabetic, and presented with a stroke rather than TIA as their qualifying event and had lower concentrations of highdensity lipoprotein cholesterol and apolipoprotein A1 compared with those who did not have an outcome stroke ( Table 2) . Table IV in the online-only Data Supplement shows Spearman r coefficients for correlations among the 13 biomarkers. None of the biomarker levels were strongly correlated (defined as a Spearman correlation coefficient r ≥0.5) with any other biomarker. Some were moderately correlated (Spearman r, 0.3-0.5). The correlated biomarkers typically reflected similar biological pathways; soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 are both leukocyte adhesion molecules, and osteopontin and neopterin are both associated with macrophage activation. Myeloperoxidase also correlated with matrix metalloproteinase-9 (MMP-9), potentially relating oxidative stress and matrix remodeling. Table V 
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December 2017 chemoattractant protein-1, resistin, and MMP-9 were no longer significant. There remained no significant relationship for hsCRP, LpPLA 2 , soluble intercellular adhesion molecule-1, N-terminal pro-B-type natriuretic peptide, soluble vascular cell adhesion molecule-1, and sCD40L. To help interpret the null results for 9 of the 13 biomarkers, the plasma concentrations for each of the 13 biomarkers in patients with and without outcome strokes are shown in Table II in the online-only Data Supplement and the statistical power to detect associations of each biomarker with outcome strokes in Table III in the online-only Data Supplement.
As several biomarkers that were tested, particularly hsCRP, are prognostic of coronary atherosclerosis outcomes, we also restricted our stroke outcome analysis to 473 individuals with documented carotid artery atherosclerosis (n=134 had outcome stroke). 12 In these participants, there remained no association of hsCRP with outcome strokes (adjusted HR per 1-SD increase in biomarker concentration, 0.908; 95% CI, 0.722-1.141; P=0.4057; n=432) whereas osteopontin continued to be associated with outcome strokes (adjusted HR, 1.445; 95% CI, 1.142-1.827; P=0.002; n=594).
Logistic regression analyses were performed to identify significant predictors of stroke (presence or absence), after adjusting for SPI-II and study treatment. Table 4 , these 3 biomarkers individually did not increase the area under the ROC curve for the prediction model of SPI-II. However, when all 3 biomarkers were included in the model, the increase in the area under the ROC curve was significant (0.023; P=0.015). Inclusion of these 3 biomarkers also resulted in a continuous NRI (29.09%; P<0.0001) and an IDI (42.68%; P<0.0001).
The SPARCL study showed that atorvastatin reduced the overall risk of outcome stroke; however, a post hoc analysis suggested an increase in treatment-associated risk of hemorrhagic strokes.
11 Table 5 provides the adjusted HRs for each biomarker separately for outcome ischemic (n=482) and hemorrhagic (n=84) strokes. Fully adjusted, osteopontin, neopterin, myeloperoxidase, and adinopectin remained associated and resistin became significantly associated with outcome ischemic strokes. Osteopontin and myeloperoxidase were also associated with outcome hemorrhagic strokes.
None of the treatment-by-biomarker interactions reached statistical significance, suggesting that atorvastatin similarly reduced the relative risk of outcome strokes regardless of baseline biomarker concentrations. The association of 13 biomarkers with outcome strokes was the same for the placebotreated and atorvastatin-treated patients, with no evidence of heterogeneity by treatment (Table VI in the online-only Data Supplement). Furthermore, the biomarker-by-on-treatment LDL cholesterol analysis was not significant, indicating that the association of osteopontin, neopterin, myoloperoxidase, and adiponectin with outcome strokes was independent of LDL cholesterol levels achieved. 
Discussion
This analysis of SPARCL trial data found that osteopontin, neopterin, myeloperoxidase, and adiponectin were each independently associated with the risk of the trial's primary end point-outcome fatal and nonfatal strokes. Surprisingly, LpPLA 2 and hsCRP, 2 inflammatory biomarkers previously associated with cardiovascular risk, were not associated with the risk of outcome strokes in SPARCL. Osteopontin, neopterin, and myeloperoxidase together improved risk prediction beyond the SPI-II assessed by increase in area under the ROC curve and reclassification (continuous NRI and IDI). There were no significant, independent relationships between any of the other tested biomarkers and outcome stroke risk. We were unable to identify prior reports of osteopontin, neopterin, myeloperoxidase, and adiponectin as independent prognostic biomarkers of recurrent strokes, and information is also limited for first strokes. The finding of a strong relationship between osteopontin levels and outcome stroke risk in SPARCL is consistent with its biology. Experimental studies implicate osteopontin as a potent mediator in the development and progression of atherosclerosis. 18, 19 Osteopontin is highly expressed in human atherosclerotic plaques, primarily derived from monocytes/macrophages 20 and is more abundant in symptomatic compared with asymptomatic carotid plaques. 21 Plasma levels of osteopontin independently predict future nonfatal myocardial infarctions and cardiovascular mortality in patients with chronic stable angina. 22 Osteopontin gene variants are associated with cardiovascular and cerebrovascular disease phenotypes. 23 We also found an association of high neopterin levels with increased risk of outcome strokes. Neopterin, a degradation product of guanosine triphosphate, is a pteridine synthesized by activated macrophages. 24 Neopterin is associated with destabilization of human coronary atherosclerotic lesions 25 and independently predicts cardiovascular events in apparently healthy individuals, 26 in chronic stable angina, 24, 26 and in acute coronary syndromes. 27 Thus, high neopterin concentrations may identify a vulnerable phenotype in both stable coronary artery disease and acute coronary syndromes. 24 Myeloperoxidase is a biomarker of oxidative injury in inflammatory states, including cardiovascular disease. Circulating myeloperoxidase predicts cardiovascular outcomes for patients with CHD, particularly those presenting with acute coronary syndrome, 28 in patients with peripheral artery disease 29 and in asymptomatic individuals. 30 Adiponectin is a 244-amino acid-long polypeptide hormone secreted by adipocytes. It has anti-inflammatory, antiatherogenic, and insulin-sensitizing effects in experimental settings. 31 Clinical studies of the relationship between adiponectin and CHD are inconsistent. In healthy individuals, high plasma adiponectin levels associate with lower risk of cardiovascular events. 32 Conversely, elevated adiponectin levels are paradoxically associated with increased risk of CHD events and mortality in higher risk individuals, particularly those with prevalent atherosclerosis. [33] [34] [35] It is hypothesized that adiponectin upregulation is protective in subjects with atherosclerosis, possibly explaining its association with high CHD event rates that might be even higher if not for adiponectin, 33 ,34 an occurrence called reverse epidemiology. 36 We similarly found that Hazard ratios associated with a 1-SD increase in log 2 -transformed biomarker values, for fatal and nonfatal stroke, unadjusted and adjusted for age, sex, race, treatment group, entry event (stroke or transient ischemic attack), time since entry event, geographic region, smoking, diabetes, systolic blood pressure, hypertension treatment, high-density lipoprotein cholesterol, and apolipoprotein A1. All treatment interaction terms were nonsignificant (all P>0.15). CI indicates confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LpPLA 2 , lipoprotein-associated phospholipase A 2 ; MCP-1, monocyte chemoattractant protein-1; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; NT-proBNP, N-terminal fragment of pro-B-type natriuretic peptide; sCD40L, soluble CD40 ligand; sICAM-1, soluble intercellular adhesion molecule-1; and sVCAM-1, soluble vascular cell adhesion molecule-1.
high adiponectin levels were associated with increased risk of outcome strokes. The association became stronger after adjustment for traditional risk factors, a finding reported previously 35 that is also consistent with reverse epidemiology. 35 The predictive capacity of the SPI-II for stroke or death was only fair in our study (ROC area under the curve, 0.6601), in agreement with data from 5 independent cohorts (ROC area under the curve, 0.62-0.65). 3 The addition of osteopontin, neopterin, and adiponectin increased the SPI-II's ROC modestly (by 0.0231; P=0.0145) and led to a highly significant NRI and IDI.
It is interesting that although all 13 biomarkers we tested have reported associations with cardiovascular outcomes other than strokes, 9 did not predict the risk of outcome strokes in the SPARCL population in fully adjusted models. SPARCL was a secondary prevention trial of subjects with a high proportion of traditional risk factors, potentially reducing the independent prognostic value of these biomarkers. We found no correlation with outcome strokes for biomarkers reflecting the recruitment of leukocytes (eg, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1), chemotaxis of monocytes/macrophages (eg, monocyte chemoattractant HR for biomarker levels associated with a 1-SD increase in log 2 -transformed biomarker values, for stroke subtypes, adjusted for age, sex, race, treatment group, entry event (stroke or transient ischemic attack), time since entry event, geographic region, smoking, diabetes mellitus, systolic blood pressure, hypertension treatment, high-density lipoprotein cholesterol, and apolipoprotein A1. CI indicates confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LpPLA 2 , lipoprotein-associated phospholipase A 2 ; MCP-1, monocyte chemoattractant protein-1; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sCD40L, soluble CD40 ligand; sICAM-1, soluble intercellular adhesion molecule-1; and sVCAM-1, soluble vascular cell adhesion molecule-1.
*There were 482 ischemic strokes and 84 hemorrhagic strokes within the substudy population.
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protein-1), extracellular matrix remodeling (eg, MMP-9), or platelet activation (eg, sCD40L). In contrast to outcome strokes, there were 8 biomarkers (among the same 13 biomarkers tested) independently associated with the occurrence of first coronary events in SPARCL in fully adjusted models, specifically monocyte chemoattractant protein-1, osteopontin, neopterin, N-terminal pro-B-type natriuretic peptide, hsCRP, myeloperoxidase, MMP-9, and adiponectin (manuscript in preparation). Differences between biomarkers prognostic of recurrent strokes and first-time coronary events suggest that the pathobiology of these processes is not identical. Although treatment with atorvastatin in the SPARCL trial reduced overall outcome strokes, it was associated with an increased risk of hemorrhagic stroke in a post hoc analysis. 11 We found an independent prognostic association for osteopontin and myeloperoxidase with hemorrhagic strokes (Table 5 ). The clinical importance of these finding is uncertain. As there were relatively few hemorrhagic strokes in the SPARCL study, the analysis may have been underpowered to detect additional biomarkers of this risk.
This study has several important strengths. It focuses on an important clinical problem-identifying patients at the highest risk of stroke after an index stroke or TIA. SPARCL provided a relatively large, well-characterized cohort of such participants. 11 The outcome strokes were adjudicated by an expert end points committee. Unlike most blood biomarker studies that focus on one or at most a few biomarkers, we simultaneously analyzed 13 biomarkers, facilitating their comparisons. We found that the addition of 3 biomarkers significantly improved risk prediction over an established predictive model (SPI-II). 3 The results of our study also highlight the potential role of monocyte/macrophages in the biology of recurrent strokes because osteopontin and neopterin reflect the vascular accumulation and activation of these cells and also the potential role of oxidative stress in recurrent strokes, exemplified by the prognostic association of myeloperoxidase.
This analysis also has limitations. Our findings suggesting relationships between the levels of osteopontin, neopterin, myeloperoxidase, and adiponectin and the risk of stroke in patients with recent stroke or TIA need to be verified in other populations. In particular, these results cannot be generalized to patients outside of the SPARCL inclusion and exclusion criteria. The prespecified analysis plan indicated that no correction would be made for multiple comparisons because of the exploratory nature of the analyses. Thus, nominal P values should be interpreted cautiously. Had we applied the most conservative Bonferroni correction to the 13 biomarker comparisons, a P≤0.0038 would be considered significant. Osteopontin, myeloperoxidase, and adiponectin would remain significantly associated with outcome strokes in fully adjusted analyses (but not neopterin, P=0.01).
The 4 biomarkers prognostic of the risk of secondary strokes in SPARCL should also be investigated as predictors of first strokes. Biomarkers that were prognostic of outcome strokes in our study may also suggest novel treatment targets. For example, osteopontin is in the causal pathway of atherosclerosis in mice, 18, 19 and thus therapeutic targeting of osteopontin might be plausible.
